Suppr超能文献

血小板生成素受体激动剂:艾曲泊帕和罗米司亭用于治疗慢性免疫性血小板减少性紫癜

Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.

作者信息

Atkinson Katie

机构信息

Weill Cornell Medicine.

出版信息

Clin J Oncol Nurs. 2019 Apr 1;23(2):212-216. doi: 10.1188/19.CJON.212-216.

Abstract

The thrombopoietin receptor agonists, eltrombopag and romiplostim, are second-line agents used to treat chronic immune thrombocytopenia purpura (ITP) in adults and children. ITP is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, petechiae, wet purpura, or blood in the urine or stool. This article reviews ITP treatment for adult and pediatric patients, including the use of the oral agent eltrombopag and the injectible agent romiplostim, nursing considerations, and patient education.

摘要

血小板生成素受体激动剂艾曲泊帕和罗米司亭是用于治疗成人及儿童慢性免疫性血小板减少性紫癜(ITP)的二线药物。ITP是一种罕见的自身免疫性疾病和血液系统疾病,其特征是血小板计数减少,可导致严重症状,如出血、瘀伤、鼻出血、瘀点、湿性紫癜或血尿或便血。本文综述了成人和儿童患者的ITP治疗,包括口服药物艾曲泊帕和注射药物罗米司亭的使用、护理注意事项及患者教育。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验